ProKidney Corp.
PROKNASDAQHealthcare● Active
$1.71
$-0.09(-5.00%)
Market Cap$574994131
P/E Ratio—
52W High$7.13
52W Low$0.54
ProKidney Corp. (PROK) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PROK · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.14
Est. -$0.13 · -7.7%
Revenue
$0.00B
Est. $0.00B · +125.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
PROK reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.13 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.13 | -$0.14 | -7.7% | $0.00B | $0.00B | +125.4% |
| ▲ Q1 FY2026 | Mar 18, 2026 | -$0.16 | -$0.14 | +12.5% | $0.00B | $0.00B | +37066.7% |
| — Q4 FY2025 | Nov 10, 2025 | -$0.12 | -$0.12 | +0.0% | $0.00B | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.14 | -$0.13 | +7.1% | $0.00B | $0.00B | +399.4% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.16 | -$0.13 | +18.8% | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 17, 2025 | -$0.14 | -$0.17 | -21.4% | $0.00B | — | — |
| — Q4 FY2024 | Nov 12, 2024 | -$0.14 | -$0.14 | +0.0% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.13
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.14
EPS Est.
-$0.13
EPS Surpr.
-7.7%
Revenue
$0.00B
Q1 FY2026
Mar 18, 2026Beat
EPS Actual
-$0.14
EPS Est.
-$0.16
EPS Surpr.
+12.5%
Revenue
$0.00B
Q4 FY2025
Nov 10, 2025
EPS Actual
-$0.12
EPS Est.
-$0.12
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.14
EPS Surpr.
+7.1%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.16
EPS Surpr.
+18.8%
Revenue
$0.00B
Q1 FY2025
Mar 17, 2025Miss
EPS Actual
-$0.17
EPS Est.
-$0.14
EPS Surpr.
-21.4%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024
EPS Actual
-$0.14
EPS Est.
-$0.14
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.11 | $-0.11 | $-0.11 | 2 |
| Q3 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q2 FY2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q1 FY2027 | $-0.16 | $-0.16 | $-0.16 | 2 |
| Q4 FY2026 | $-0.17 | $-0.17 | $-0.17 | 2 |
| Q3 FY2026 | $-0.19 | $-0.17 | $-0.16 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -7.7% | $1.71 | $1.66 | -2.92% |
| ▲ Q1 FY2026 | Mar 18, 2026 | +12.5% | $2.13 | $2.08 | -2.35% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +0.0% | $2.89 | $2.70 | -6.57% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +7.1% | $2.26 | $2.24 | -0.88% |
| ▲ Q2 FY2025 | May 12, 2025 | +18.8% | $0.72 | $0.75 | +3.96% |
| ▼ Q1 FY2025 | Mar 17, 2025 | -21.4% | $0.98 | $1.04 | +5.73% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +0.0% | $2.15 | $2.05 | -4.65% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +5.9% | $2.09 | $2.18 | +4.31% |
Q2 FY2026-2.92%
Report Date
May 15, 2026
EPS Beat/Miss
-7.7%
Price Before
$1.71
Price After
$1.66
Q1 FY2026-2.35%
Report Date
Mar 18, 2026
EPS Beat/Miss
+12.5%
Price Before
$2.13
Price After
$2.08
Q4 FY2025-6.57%
Report Date
Nov 10, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.89
Price After
$2.70
Q3 FY2025-0.88%
Report Date
Aug 12, 2025
EPS Beat/Miss
+7.1%
Price Before
$2.26
Price After
$2.24
Q2 FY2025+3.96%
Report Date
May 12, 2025
EPS Beat/Miss
+18.8%
Price Before
$0.72
Price After
$0.75
Q1 FY2025+5.73%
Report Date
Mar 17, 2025
EPS Beat/Miss
-21.4%
Price Before
$0.98
Price After
$1.04
Q4 FY2024-4.65%
Report Date
Nov 12, 2024
EPS Beat/Miss
+0.0%
Price Before
$2.15
Price After
$2.05
Q3 FY2024+4.31%
Report Date
Aug 9, 2024
EPS Beat/Miss
+5.9%
Price Before
$2.09
Price After
$2.18
Avg Beat Reaction-1.03%
Avg Miss Reaction+1.41%
Beat Rate6 / 8 quarters
Largest Move-6.57% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PROK ends December
ProKidney Corp. (PROK) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.14 — missing the analyst consensus of $-0.13 by -7.7%. The next PROK earnings date is expected around September 1, 2026.
Each quarter, investors track PROK earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PROK revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PROK's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PROK earnings · 5 questionsProKidney Corp.'s next earnings report is expected around September 1, 2026. PROK typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PROK historically reports after market close (AMC).
PROK earnings datewhen is PROK earningsPROK next earnings datewhen does PROK report earningsPROK earnings calendar
▸ Source: FMP · ProKidney Corp. SEC filings · US GAAP · ProKidney Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026